PlaqueTec and the Babraham Institute collaborate on early phase target discovery and development

PlaqueTec, a company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), based at the Babraham Research Campus, and the Welch research group at the Babraham Institute today announced the successful completion of a collaboration to evaluate lead compounds predicted to bind a pro-inflammatory protein discovered by PlaqueTec in pilot studies.

The project was funded by the UKRI-BBSRC Campus Innovation Award (CIA), via the Babraham Research Campus Collaboration Fund in October 2023.

PlaqueTec and the Welch research group, focused on research into cell signalling and led by Dr Heidi Welch, tested the pro-inflammatory protein in a human cell culture model, demonstrating its potential to be targeted by small molecule drugs—opening new opportunities for a precision medicine approach to heart disease. The target is now being evaluated as part of PlaqueTec’s ongoing BIOPATTERN trial and, if validated, further development will be pursued.

Dr Simon Williams, General Manager, PlaqueTec, commented: “The successful completion of our latest collaboration with the Babraham Institute is an encouraging demonstration that new disease-specific targets identified by PlaqueTec have the potential to be modifiable by small molecule drugs. As we continue our BIOPATTERN trial, we are confident that our unique approach to endotyping CAD will pave the way for a new era of precision medicine for millions of patients with the disease.”

Dr Heidi Welch, Associate Group Leader, Signalling Research Programme at the Babraham Institute, added: “Our work is focused on the molecular mechanisms that control a specific family of proteins, particularly in inflammatory cells, and we are delighted to have leveraged this expertise in an early phase target discovery and development project with PlaqueTec for its recently discovered pro-inflammatory protein target. Following the success of this collaboration, we are excited to see this novel drug target undergo further evaluation in PlaqueTec’s BIOPATTERN trial.”

Derek Jones, Chief Executive of Babraham Research Campus, said: "The UKRI-BBSRC Campus Innovation Award was initiated last year to give individuals and companies on Campus access to a unique tranche of funding not available elsewhere. We are therefore delighted to see the success of the collaboration between PlaqueTec and the Welch research group to date and look forward to further updates once evaluation via PlaqueTec’s BIOPATTERN trial is concluded.”

In February 2022, PlaqueTec was awarded Innovate UK Business Growth funding to collaborate with Medicines Discovery Catapult to work on a pilot project aimed at identifying novel drug targets in CAD. Data obtained for this earlier project formed the basis for the current CIA-funded project to evaluate lead compounds against one of the targets identified.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    PlaqueTec. (2024, May 14). PlaqueTec and the Babraham Institute collaborate on early phase target discovery and development. News-Medical. Retrieved on June 13, 2024 from https://www.news-medical.net/news/20240514/PlaqueTec-and-the-Babraham-Institute-collaborate-on-early-phase-target-discovery-and-development.aspx.

  • MLA

    PlaqueTec. "PlaqueTec and the Babraham Institute collaborate on early phase target discovery and development". News-Medical. 13 June 2024. <https://www.news-medical.net/news/20240514/PlaqueTec-and-the-Babraham-Institute-collaborate-on-early-phase-target-discovery-and-development.aspx>.

  • Chicago

    PlaqueTec. "PlaqueTec and the Babraham Institute collaborate on early phase target discovery and development". News-Medical. https://www.news-medical.net/news/20240514/PlaqueTec-and-the-Babraham-Institute-collaborate-on-early-phase-target-discovery-and-development.aspx. (accessed June 13, 2024).

  • Harvard

    PlaqueTec. 2024. PlaqueTec and the Babraham Institute collaborate on early phase target discovery and development. News-Medical, viewed 13 June 2024, https://www.news-medical.net/news/20240514/PlaqueTec-and-the-Babraham-Institute-collaborate-on-early-phase-target-discovery-and-development.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.